G protein-coupled receptor kinase 5 modifies cancer cell resistance to paclitaxel.
Acetylation
Apoptosis
/ drug effects
Biocatalysis
/ drug effects
Breast Neoplasms
/ metabolism
Docetaxel
/ pharmacology
Drug Resistance, Neoplasm
/ drug effects
Female
G-Protein-Coupled Receptor Kinase 3
/ metabolism
G-Protein-Coupled Receptor Kinase 5
/ metabolism
G-Protein-Coupled Receptor Kinases
/ metabolism
HeLa Cells
Histone Deacetylase 6
/ metabolism
Histones
/ metabolism
Humans
MAP Kinase Signaling System
/ drug effects
Paclitaxel
/ pharmacology
Phosphorylation
/ drug effects
Phosphoserine
/ metabolism
Protein Binding
/ drug effects
Tubulin
/ metabolism
Acetylation
Cancer
G protein-coupled receptor kinase
Histone deacetylase
Paclitaxel
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
13
02
2019
accepted:
22
07
2019
pubmed:
1
8
2019
medline:
9
1
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
G protein-coupled receptor kinases (GRKs) phosphorylate the activated forms of G protein-coupled receptors (GPCRs), leading to receptor desensitization and internalization. In addition, GRKs can modify the activity of many non-GPCR-signaling pathways as well, controlling other cellular functions beyond that directly associated with a GPCR. In this report, we show that cervical cancer HeLa cells and breast cancer MDA MB 231 cells with reduced GRK5 expression display increased sensitivity to the apoptotic effects of paclitaxel (Taxol). This effect in cancer cells with low GRK5 levels could be because of blunted histone deacetylase 6 (HDAC6) activity that leads to an increase in α-tubulin acetylation levels, which augments paclitaxel sensitivity. We demonstrate that GRK5 and HDAC6 form a signaling complex in cells and in vitro. GRK5 phosphorylates HDAC6 at Ser-21 to promote its deacetylase activity. Therefore, the GRK5-HDAC6 interaction may contribute to paclitaxel resistance in cancer cells.
Identifiants
pubmed: 31363957
doi: 10.1007/s11010-019-03594-9
pii: 10.1007/s11010-019-03594-9
doi:
Substances chimiques
Histones
0
Tubulin
0
Docetaxel
15H5577CQD
Phosphoserine
17885-08-4
G-Protein-Coupled Receptor Kinase 3
EC 2.7.11.15
GRK3 protein, human
EC 2.7.11.15
G-Protein-Coupled Receptor Kinase 5
EC 2.7.11.16
G-Protein-Coupled Receptor Kinases
EC 2.7.11.16
G-protein-coupled receptor kinase 6
EC 2.7.11.16
GRK5 protein, human
EC 2.7.11.16
HDAC6 protein, human
EC 3.5.1.98
Histone Deacetylase 6
EC 3.5.1.98
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-118Références
Long HJ (1994) Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc 69:341–345
doi: 10.1016/S0025-6196(12)62219-8
pubmed: 7909575
Frederiks CN, Lam SW, Guchelaar HJ, Boven E (2015) Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: a systematic review. Cancer Treat Rev 41:935–950. https://doi.org/10.1016/j.ctrv.2015.10.010
doi: 10.1016/j.ctrv.2015.10.010
pubmed: 26585358
Gelmon K (1994) The taxoids: paclitaxel and docetaxel. Lancet 344:1267–1272
doi: 10.1016/S0140-6736(94)90754-4
pubmed: 7967989
Carvalho A, Carmena M, Sambade C, Earnshaw WC, Wheatley SP (2003) Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. J Cell Sci 116:2987–2998. https://doi.org/10.1242/jcs.00612
doi: 10.1242/jcs.00612
pubmed: 12783991
Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194–204. https://doi.org/10.1038/nrc2803
doi: 10.1038/nrc2803
pubmed: 20147901
Yagi H, Yotsumoto F, Sonoda K, Kuroki M, Mekada E, Miyamoto S (2009) Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int J Cancer 124:1429–1439. https://doi.org/10.1002/ijc.24031
doi: 10.1002/ijc.24031
pubmed: 19048624
Moore CA, Milano SK, Benovic JL (2007) Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69:451–482. https://doi.org/10.1146/annurev.physiol.69.022405.154712
doi: 10.1146/annurev.physiol.69.022405.154712
pubmed: 17037978
Cant SH, Pitcher JA (2005) G protein-coupled receptor kinase 2-mediated phosphorylation of ezrin is required for G protein-coupled receptor-dependent reorganization of the actin cytoskeleton. Mol Biol Cell 16:3088–3099. https://doi.org/10.1091/mbc.E04-10-0877
doi: 10.1091/mbc.E04-10-0877
pubmed: 15843435
pmcid: 1165394
Martini JS, Raake P, Vinge LE, DeGeorge BR, DeGeorge B, Chuprun JK, Harris DM, Gao E, Eckhart AD, Pitcher JA, Koch WJ (2008) Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc Natl Acad Sci USA 105:12457–12462. https://doi.org/10.1073/pnas.0803153105
doi: 10.1073/pnas.0803153105
pubmed: 18711143
pmcid: 2527933
Carman CV, Som T, Kim CM, Benovic JL (1998) Binding and phosphorylation of tubulin by G protein-coupled receptor kinases. J Biol Chem 273:20308–20316
doi: 10.1074/jbc.273.32.20308
pubmed: 9685381
Barthet G, Carrat G, Cassier E, Barker B, Gaven F, Pillot M, Framery B, Pellissier LP, Augier J, Kang DS, Claeysen S, Reiter E, Baneres JL, Benovic JL, Marin P, Bockaert J, Dumuis A (2009) Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signalling. EMBO J 28:2706–2718. https://doi.org/10.1038/emboj.2009.215
doi: 10.1038/emboj.2009.215
pubmed: 19661922
pmcid: 2750015
Barker BL, Benovic JL (2011) G protein-coupled receptor kinase 5 phosphorylation of hip regulates internalization of the chemokine receptor CXCR12. Biochemistry 50:6933–6941. https://doi.org/10.1021/bi2005202
doi: 10.1021/bi2005202
pubmed: 21728385
Pronin AN, Morris AJ, Surguchov A, Benovic JL (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275:26515–26522. https://doi.org/10.1074/jbc.M003542200
doi: 10.1074/jbc.M003542200
pubmed: 10852916
Chen X, Zhu H, Yuan M, Fu J, Zhou Y, Ma L (2010) G-protein-coupled receptor kinase 5 phosphorylates p53 and inhibits DNA damage-induced apoptosis. J Biol Chem 285:12823–12830. https://doi.org/10.1074/jbc.M109.094243
doi: 10.1074/jbc.M109.094243
pubmed: 20124405
pmcid: 2857122
Ruiz-Gomez A, Humrich J, Murga C, Quitterer U, Lohse MJ, Mayor F Jr (2000) Phosphorylation of phosducin and phosducin-like protein by G protein-coupled receptor kinase 2. J Biol Chem 275:29724–29730. https://doi.org/10.1074/jbc.M001864200
doi: 10.1074/jbc.M001864200
pubmed: 10884381
Peregrin S, Jurado-Pueyo M, Campos PM, Sanz-Moreno V, Ruiz-Gomez A, Crespo P, Mayor F, Murga C (2006) Phosphorylation of p38 by GRK2 at the docking groove unveils a novel mechanism for inactivating p38MAPK. Curr Biol 16:2042–2047. https://doi.org/10.1016/j.cub.2006.08.083
doi: 10.1016/j.cub.2006.08.083
pubmed: 17055984
Patial S, Luo J, Porter KJ, Benovic JL, Parameswaran N (2009) G-protein-coupled-receptor kinases mediate TNFalpha-induced NFkappaB signalling via direct interaction with and phosphorylation of IkappaBalpha. Biochem J 425:169–178. https://doi.org/10.1042/bj20090908
doi: 10.1042/bj20090908
pubmed: 19796012
Parameswaran N, Pao CS, Leonhard KS, Kang DS, Kratz M, Ley SC, Benovic JL (2006) Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide-stimulated ERK1/2 activation in macrophages. J Biol Chem 281:34159–34170. https://doi.org/10.1074/jbc.M605376200
doi: 10.1074/jbc.M605376200
pubmed: 16980301
So CH, Michal A, Komolov KE, Luo J, Benovic JL (2013) G protein-coupled receptor kinase 2 (GRK2) is localized to centrosomes and mediates epidermal growth factor-promoted centrosomal separation. Mol Biol Cell 24:2795–2806. https://doi.org/10.1091/mbc.E13-01-0013
doi: 10.1091/mbc.E13-01-0013
pubmed: 23904266
pmcid: 3771943
Chakraborty PK, Zhang Y, Coomes AS, Kim WJ, Stupay R, Lynch LD, Atkinson T, Kim JI, Nie Z, Daaka Y (2014) G protein-coupled receptor kinase GRK5 phosphorylates moesin and regulates metastasis in prostate cancer. Cancer Res 74:3489–3500. https://doi.org/10.1158/0008-5472.CAN-13-2708
doi: 10.1158/0008-5472.CAN-13-2708
pubmed: 24755472
Ruiz-Gomez A, Mellstrom B, Tornero D, Morato E, Savignac M, Holguin H, Aurrekoetxea K, Gonzalez P, Gonzalez-Garcia C, Cena V, Mayor F Jr, Naranjo JR (2007) G protein-coupled receptor kinase 2-mediated phosphorylation of downstream regulatory element antagonist modulator regulates membrane trafficking of Kv4.2 potassium channel. J Biol Chem 282:1205–1215. https://doi.org/10.1074/jbc.M607166200
doi: 10.1074/jbc.M607166200
pubmed: 17102134
Singhmar P, Huo X, Eijkelkamp N, Berciano SR, Baameur F, Mei FC, Zhu Y, Cheng X, Hawke D, Mayor F Jr, Murga C, Heijnen CJ, Kavelaars A (2016) Critical role for Epac1 in inflammatory pain controlled by GRK2-mediated phosphorylation of Epac1. Proc Natl Acad Sci USA 113:3036–3041. https://doi.org/10.1073/pnas.1516036113
doi: 10.1073/pnas.1516036113
pubmed: 26929333
pmcid: 4801297
Ohba Y, Nakaya M, Watari K, Nagasaka A, Kurose H (2015) GRK6 phosphorylates IκBα at Ser(32)/Ser(36) and enhances TNF-α-induced inflammation. Biochem Biophys Res Commun 461:307–313. https://doi.org/10.1016/j.bbrc.2015.04.027
doi: 10.1016/j.bbrc.2015.04.027
pubmed: 25881508
Penela P, Rivas V, Salcedo A, Mayor F (2010) G protein-coupled receptor kinase 2 (GRK2) modulation and cell cycle progression. Proc Natl Acad Sci USA 107:1118–1123. https://doi.org/10.1073/pnas.0905778107
doi: 10.1073/pnas.0905778107
pubmed: 20080565
Fu X, Koller S, Abd Alla J, Quitterer U (2013) Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway. J Biol Chem 288:7738–7755. https://doi.org/10.1074/jbc.M112.428078
doi: 10.1074/jbc.M112.428078
pubmed: 23362259
pmcid: 3597814
Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, Li M, Xu J, Zhang S, Ittmann M, Li W (2016) GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. Oncotarget 7:45171–45185. https://doi.org/10.18632/oncotarget.9359
doi: 10.18632/oncotarget.9359
pubmed: 27191986
pmcid: 5216714
Theccanat T, Philip JL, Razzaque AM, Ludmer N, Li J, Xu X, Akhter SA (2016) Regulation of cellular oxidative stress and apoptosis by G protein-coupled receptor kinase-2; the role of NADPH oxidase 4. Cell Signal 28:190–203. https://doi.org/10.1016/j.cellsig.2015.11.013
doi: 10.1016/j.cellsig.2015.11.013
pubmed: 26631573
Métayé T, Levillain P, Kraimps JL, Perdrisot R (2008) Immunohistochemical detection, regulation and antiproliferative function of G-protein-coupled receptor kinase 2 in thyroid carcinomas. J Endocrinol 198:101–110. https://doi.org/10.1677/JOE-07-0562
doi: 10.1677/JOE-07-0562
pubmed: 18451066
Métayé T, Menet E, Guilhot J, Kraimps JL (2002) Expression and activity of g protein-coupled receptor kinases in differentiated thyroid carcinoma. J Clin Endocrinol Metab 87:3279–3286. https://doi.org/10.1210/jcem.87.7.8618
doi: 10.1210/jcem.87.7.8618
pubmed: 12107237
Billard MJ, Fitzhugh DJ, Parker JS, Brozowski JM, McGinnis MW, Timoshchenko RG, Serafin DS, Lininger R, Klauber-Demore N, Sahagian G, Truong YK, Sassano MF, Serody JS, Tarrant TK (2016) G protein coupled receptor kinase 3 regulates breast cancer migration, invasion, and metastasis. PLoS ONE 11:e0152856. https://doi.org/10.1371/journal.pone.0152856
doi: 10.1371/journal.pone.0152856
pubmed: 27049755
pmcid: 4822790
Kaur G, Kim J, Kaur R, Tan I, Bloch O, Sun MZ, Safaee M, Oh MC, Sughrue M, Phillips J, Parsa AT (2013) G-protein coupled receptor kinase (GRK)-5 regulates proliferation of glioblastoma-derived stem cells. J Clin Neurosci 20:1014–1018. https://doi.org/10.1016/j.jocn.2012.10.008
doi: 10.1016/j.jocn.2012.10.008
pubmed: 23693024
Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, Benovic JL, Piwnica-Worms D, Rubin JB (2012) Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth. Mol Cancer Res 10:156–166. https://doi.org/10.1158/1541-7786.MCR-11-0411
doi: 10.1158/1541-7786.MCR-11-0411
pubmed: 22086906
Nogues L, Reglero C, Rivas V, Salcedo A, Lafarga V, Neves M, Ramos P, Mendiola M, Berjon A, Stamatakis K, Zhou XZ, Lu KP, Hardisson D, Mayor F Jr, Penela P (2016) G protein-coupled receptor kinase 2 (GRK2) promotes breast tumorigenesis through a HDAC6-Pin1 axis. EBioMedicine 13:132–145. https://doi.org/10.1016/j.ebiom.2016.09.030
doi: 10.1016/j.ebiom.2016.09.030
pubmed: 27720394
pmcid: 5264252
So CH, Michal AM, Mashayekhi R, Benovic JL (2012) G protein-coupled receptor kinase 5 phosphorylates nucleophosmin and regulates cell sensitivity to polo-like kinase 1 inhibition. J Biol Chem 287:17088–17099. https://doi.org/10.1074/jbc.M112.353854
doi: 10.1074/jbc.M112.353854
pubmed: 22467873
pmcid: 3366848
Michal AM, So CH, Beeharry N, Shankar H, Mashayekhi R, Yen TJ, Benovic JL (2012) G Protein-coupled receptor kinase 5 is localized to centrosomes and regulates cell cycle progression. J Biol Chem 287:6928–6940. https://doi.org/10.1074/jbc.M111.298034
doi: 10.1074/jbc.M111.298034
pubmed: 22223642
pmcid: 3307296
Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G (2007) Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 14:839–845. https://doi.org/10.1677/erc-07-0096
doi: 10.1677/erc-07-0096
pubmed: 17914112
Lafarga V, Aymerich I, Tapia O, Mayor F Jr, Penela P (2012) A novel GRK2/HDAC6 interaction modulates cell spreading and motility. EMBO J 31:856–869. https://doi.org/10.1038/emboj.2011.466
doi: 10.1038/emboj.2011.466
pubmed: 22193721
Du Y, Seibenhener ML, Yan J, Jiang J, Wooten MC (2015) aPKC phosphorylation of HDAC6 results in increased deacetylation activity. PLoS ONE 10:e0123191. https://doi.org/10.1371/journal.pone.0123191
doi: 10.1371/journal.pone.0123191
pubmed: 25860570
pmcid: 4393284
Kunapuli P, Benovic JL (1993) Cloning and expression of GRK5: a member of the G protein-coupled receptor kinase family. Proc Natl Acad Sci USA 90:5588–5592. https://doi.org/10.1073/pnas.90.12.5588
doi: 10.1073/pnas.90.12.5588
pubmed: 7685906
pmcid: 46766
Spencer ML, Theodosiou M, Noonan DJ (2004) NPDC-1, a novel regulator of neuronal proliferation, is degraded by the ubiquitin/proteasome system through a PEST degradation motif. J Biol Chem 279:37069–37078. https://doi.org/10.1074/jbc.M402507200
doi: 10.1074/jbc.M402507200
pubmed: 15229225
Skoufias DA, Wilson L (1992) Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 31:738–746
doi: 10.1021/bi00118a015
pubmed: 1731931
Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L (1997) Nanomolar concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. Mol Biol Cell 8:973–985
doi: 10.1091/mbc.8.6.973
pubmed: 9201709
pmcid: 305707
Xu R, Sato N, Yanai K, Akiyoshi T, Nagai S, Wada J, Koga K, Mibu R, Nakamura M, Katano M (2009) Enhancement of paclitaxel-induced apoptosis by inhibition of mitogen-activated protein kinase pathway in colon cancer cells. Anticancer Res 29:261–270
pubmed: 19331159
Sallmann FR, Bourassa S, Saint-Cyr J, Poirier GG (1997) Characterization of antibodies specific for the caspase cleavage site on poly(ADP-ribose) polymerase: specific detection of apoptotic fragments and mapping of the necrotic fragments of poly(ADP-ribose) polymerase. Biochem Cell Biol 75:451–456
doi: 10.1139/o97-075
pubmed: 9493968
Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K, Verma AK, Terada LS, Platanias LC, Parmar S (2009) Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 50:2017–2029. https://doi.org/10.3109/10428190903147637
doi: 10.3109/10428190903147637
pubmed: 19672773
pmcid: 2888505
Aslan Kosar P, Tuncer H, Cihangir Uguz A, Espino Palma J, Darici H, Onaran I, Cig B, Kosar A, Rodriguez Moratinos AB (2015) The efficiency of poly(ADP-Ribose) polymerase (PARP) cleavage on detection of apoptosis in an experimental model of testicular torsion. Int J Exp Pathol 96:294–300. https://doi.org/10.1111/iep.12137
doi: 10.1111/iep.12137
pubmed: 26303136
pmcid: 4693552
Liu X, Erikson RL (2003) Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 100:5789–5794. https://doi.org/10.1073/pnas.1031523100
doi: 10.1073/pnas.1031523100
pubmed: 12732729
pmcid: 156279
Butch ER, Guan KL (1996) Characterization of ERK1 activation site mutants and the effect on recognition by MEK1 and MEK2. J Biol Chem 271:4230–4235
doi: 10.1074/jbc.271.8.4230
pubmed: 8626767
Hu J, Zhang NA, Wang R, Huang F, Li G (2015) Paclitaxel induces apoptosis and reduces proliferation by targeting epidermal growth factor receptor signaling pathway in oral cavity squamous cell carcinoma. Oncol Lett 10:2378–2384. https://doi.org/10.3892/ol.2015.3499
doi: 10.3892/ol.2015.3499
pubmed: 26622855
pmcid: 4580028
Perdiz D, Mackeh R, Pous C, Baillet A (2011) The ins and outs of tubulin acetylation: more than just a post-translational modification? Cell Signal 23:763–771. https://doi.org/10.1016/j.cellsig.2010.10.014
doi: 10.1016/j.cellsig.2010.10.014
pubmed: 20940043
Sobue S, Mizutani N, Aoyama Y, Kawamoto Y, Suzuki M, Nozawa Y, Ichihara M, Murate T (2016) Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel. Biochem Biophys Res Commun 479:808–813. https://doi.org/10.1016/j.bbrc.2016.09.128
doi: 10.1016/j.bbrc.2016.09.128
pubmed: 27687545
Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE (2002) Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1:937–941
pubmed: 12481415
Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP (2002) HDAC6 is a microtubule-associated deacetylase. Nature 417:455–458. https://doi.org/10.1038/417455a
doi: 10.1038/417455a
pubmed: 12024216
Chen S, Owens GC, Makarenkova H, Edelman DB (2010) HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS ONE 5:e10848. https://doi.org/10.1371/journal.pone.0010848
doi: 10.1371/journal.pone.0010848
pubmed: 20520769
pmcid: 2877100
Williams KA, Zhang M, Xiang S, Hu C, Wu JY, Zhang S, Ryan M, Cox AD, Der CJ, Fang B, Koomen J, Haura E, Bepler G, Nicosia SV, Matthias P, Wang C, Bai W, Zhang X (2013) Extracellular signal-regulated kinase (ERK) phosphorylates histone deacetylase 6 (HDAC6) at serine 1035 to stimulate cell migration. J Biol Chem 288:33156–33170. https://doi.org/10.1074/jbc.M113.472506
doi: 10.1074/jbc.M113.472506
pubmed: 24089523
pmcid: 3829163
Scharer CD, Laycock N, Osunkoya AO, Logani S, McDonald JF, Benigno BB, Moreno CS (2008) Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 6:79. https://doi.org/10.1186/1479-5876-6-79
doi: 10.1186/1479-5876-6-79
pubmed: 19077237
pmcid: 2614415
Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, Berndt A, Richter P, D’Incalci M, Cavalletti E, Giavazzi R, Camboni G, Damia G (2013) The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther 12:131–140. https://doi.org/10.1158/1535-7163.mct-12-0275-t
doi: 10.1158/1535-7163.mct-12-0275-t
pubmed: 23270924
Homan KT, Waldschmidt HV, Glukhova A, Cannavo A, Song J, Cheung JY, Koch WJ, Larsen SD, Tesmer JJ (2015) Crystal structure of G protein-coupled receptor kinase 5 in complex with a rationally designed inhibitor. J Biol Chem 290:20649–20659. https://doi.org/10.1074/jbc.M115.647370
doi: 10.1074/jbc.M115.647370
pubmed: 26032411
pmcid: 4543626
Schumacher SM, Gao E, Zhu W, Chen X, Chuprun JK, Feldman AM, Tesmer JJ, Koch WJ (2015) Paroxetine-mediated GRK2 inhibition reverses cardiac dysfunction and remodeling after myocardial infarction. Sci Transl Med 7:277ra31. https://doi.org/10.1126/scitranslmed.aaa0154
doi: 10.1126/scitranslmed.aaa0154
pubmed: 25739765
pmcid: 4768806
Howes SC, Alushin GM, Shida T, Nachury MV, Nogales E (2014) Effects of tubulin acetylation and tubulin acetyltransferase binding on microtubule structure. Mol Biol Cell 25:257–266. https://doi.org/10.1091/mbc.E13-07-0387
doi: 10.1091/mbc.E13-07-0387
pubmed: 24227885
pmcid: 3890346
Liu W, Fan LX, Zhou X, Sweeney WE Jr, Avner ED, Li X (2012) HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS ONE 7:e49418. https://doi.org/10.1371/journal.pone.0049418
doi: 10.1371/journal.pone.0049418
pubmed: 23152903
pmcid: 3496684
Liu Y, Peng L, Seto E, Huang S, Qiu Y (2012) Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation. J Biol Chem 287:29168–29174. https://doi.org/10.1074/jbc.M112.371120
doi: 10.1074/jbc.M112.371120
pubmed: 22778253
pmcid: 3436516
Palazzo A, Ackerman B, Gundersen GG (2003) Cell biology: tubulin acetylation and cell motility. Nature 421:230. https://doi.org/10.1038/421230a
doi: 10.1038/421230a
pubmed: 12529632
Yagi Y, Fushida S, Harada S, Kinoshita J, Makino I, Oyama K, Tajima H, Fujita H, Takamura H, Ninomiya I, Fujimura T, Ohta T, Yashiro M, Hirakawa K (2010) Effects of valproic acid on the cell cycle and apoptosis through acetylation of histone and tubulin in a scirrhous gastric cancer cell line. J Exp Clin Cancer Res 29:149. https://doi.org/10.1186/1756-9966-29-149
doi: 10.1186/1756-9966-29-149
pubmed: 21080974
pmcid: 2994814
Kim SH, Juhnn YS, Song YS (2007) Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 1095:82–89. https://doi.org/10.1196/annals.1397.012
doi: 10.1196/annals.1397.012
pubmed: 17404021
Bae T, Weon KY, Lee JW, Eum KH, Kim S, Choi JW (2015) Restoration of paclitaxel resistance by CDK1 intervention in drug-resistant ovarian cancer. Carcinogenesis 36:1561–1571. https://doi.org/10.1093/carcin/bgv140
doi: 10.1093/carcin/bgv140
pubmed: 26442525
Shi X, Sun X (2017) Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy. Cancer Chemother Pharmacol 80:909–917. https://doi.org/10.1007/s00280-017-3398-2
doi: 10.1007/s00280-017-3398-2
pubmed: 28741098
Fujioka H, Sakai A, Tanaka S, Kimura K, Miyamoto A, Iwamoto M, Uchiyama K (2017) Comparative proteomic analysis of paclitaxel resistance-related proteins in human breast cancer cell lines. Oncol Lett 13:289–295. https://doi.org/10.3892/ol.2016.5455
doi: 10.3892/ol.2016.5455
pubmed: 28123557
Kramer OH, Mahboobi S, Sellmer A (2014) Drugging the HDAC6-HSP90 interplay in malignant cells. Trends Pharmacol Sci 35:501–509. https://doi.org/10.1016/j.tips.2014.08.001
doi: 10.1016/j.tips.2014.08.001
pubmed: 25234862
Di Fulvio S, Azakir BA, Therrien C, Sinnreich M (2011) Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS ONE 6:e28563. https://doi.org/10.1371/journal.pone.0028563
doi: 10.1371/journal.pone.0028563
pubmed: 22174839
pmcid: 3234273
Wu Y, Song SW, Sun J, Bruner JM, Fuller GN, Zhang W (2010) IIp45 inhibits cell migration through inhibition of HDAC6. J Biol Chem 285:3554–3560. https://doi.org/10.1074/jbc.M109.063354
doi: 10.1074/jbc.M109.063354
pubmed: 20008322
Lernoux M, Schnekenburger M, Dicato M, Diederich M (2017) Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacol Res. https://doi.org/10.1016/j.phrs.2017.11.004
doi: 10.1016/j.phrs.2017.11.004
pubmed: 29133216
Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, Yao TP, Lane WS, Seto E (2007) HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 27:197–213. https://doi.org/10.1016/j.molcel.2007.05.033
doi: 10.1016/j.molcel.2007.05.033
pubmed: 17643370
pmcid: 2684874
Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP (2005) HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 18:601–607. https://doi.org/10.1016/j.molcel.2005.04.021
doi: 10.1016/j.molcel.2005.04.021
pubmed: 15916966
Garmpis N, Damaskos C, Garmpi A, Dimitroulis D, Spartalis E, Margonis GA, Schizas D, Deskou I, Doula C, Magkouti E, Andreatos N, Antoniou EA, Nonni A, Kontzoglou K, Mantas D (2017) Targeting histone deacetylases in malignant melanoma: a future therapeutic agent or just great expectations? Anticancer Res 37:5355–5362. https://doi.org/10.21873/anticanres.11961
doi: 10.21873/anticanres.11961
pubmed: 28982843
Glozak MA, Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420–5432. https://doi.org/10.1038/sj.onc.1210610
doi: 10.1038/sj.onc.1210610
pubmed: 17694083
Komolov KE, Du Y, Duc NM, Betz RM, Rodrigues J, Leib RD, Patra D, Skiniotis G, Adams CM, Dror RO, Chung KY, Kobilka BK, Benovic JL (2017) Structural and functional analysis of a beta2-adrenergic receptor complex with grk5. Cell 169:407–421.e16. https://doi.org/10.1016/j.cell.2017.03.047
doi: 10.1016/j.cell.2017.03.047
pubmed: 28431242
pmcid: 5526774
Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (taxol) in human tumour cell lines. Br J Cancer 68:1104–1109. https://doi.org/10.1038/bjc.1993.488
doi: 10.1038/bjc.1993.488
pubmed: 7903152
pmcid: 1968657
Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli UA, Baran Y, Uslu R (2009) Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 33:239–246. https://doi.org/10.1016/j.cellbi.2008.11.011
doi: 10.1016/j.cellbi.2008.11.011
pubmed: 19103299
Low SY, Rennie MJ, Taylor PM (1997) Involvement of integrins and the cytoskeleton in modulation of skeletal muscle glycogen synthesis by changes in cell volume. FEBS Lett 417:101–103
doi: 10.1016/S0014-5793(97)01264-7
pubmed: 9395084
Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH (2002) G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 110:91–99. https://doi.org/10.1172/jci13275
doi: 10.1172/jci13275
pubmed: 12093892
pmcid: 151025